Home
On-Demand
Industrie
FAQ
Login MyUpdate
Home
On-Demand
Industrie
FAQ
Login MyUpdate
Schlagwort
Fuzuloparib
Ovarialkarzinom – Systemtherapie
Ovarialkarzinom – Systemtherapie
1st Line Immuntherapie
/
Apatinib
/
bevacizumab
/
BRCA
/
Dostarlimab
/
DUO-O
/
endometrioiden „NSMP“ Ovarialkarzinom
/
ER-Expression
/
fortgeschrittenen Ovarialkarzinoms
/
Fuzuloparib
/
Genomic Instability Score (GIS)
/
ICON8B
/
KELIM
/
KEYNOTE-B96
/
NAPISTAR-01
/
neoadjuvanter Chemotherapie
/
Niraparib
/
Olaparib
/
PAOLA-1-Studie
/
PARPi-Erhaltungsgherapie
/
Pembrolizumab
/
Platin-haltige Chemotherapie
/
Primärtherapie
/
Rezidivtherapie
/
ROSELLA
Ovarialkarzinom – Systemtherapie
Ovarialkarzinom – Systemtherapie
Antiangiogenese
/
Ariel-4-Studie
/
ATALANTE-Studie
/
ATHENA–MONO-Studie
/
bevacizumab
/
Cediranib
/
Fuzuloparib
/
Gemcitabine
/
Immunonkologie
/
LGSOC
/
Nivolumab
/
Olaparib
/
Ovarialkarzinom
/
PARPi
/
Rucaparib
